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Abstract
Patients presenting with pleural effusion of undetermined aetiology were prospectively enrolled, and an enzyme-linked immunospot
(ELISPOT) assay on pleural ﬂuid and peripheral blood was performed. Forty patients were studied, including 19 with culture- or biopsy-con-
ﬁrmed (n = 15) or clinically compatible (n = 4) tuberculous pleurisy, and 21 with pleural effusions due to non-tuberculous causes. The sensi-
tivity, speciﬁcity and positive and negative predictive values of the assay were 94.7%, 85.7%, 85.7% and 94.7%, respectively, on pleural ﬂuid,
and 77.8%, 90.5%, 87.5% and 82.6%, respectively, on blood. Antigen-speciﬁc, interferon-gamma-secreting T-cells were concentrated eight
to ten times in pleural ﬂuid as compared with blood. Among the seven patients not suitable for pleural biopsy and three patients whose biopsy
results were non-diagnostic, nine had positive ELISPOT result with pleural ﬂuid. The ELISPOT assay for interferon-gamma can accurately
diagnose tuberculous pleurisy and is helpful for patients not suitable for pleural biopsy and those whose biopsy results are non-diagnostic.
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Introduction
Tuberculous pleurisy is an important cause of pleural effu-
sions, and may account for 14% of all pleural exudates, or
25% of all pleural effusions, in areas with a high incidence of
tuberculosis [1–3]. Conventional methods for the diagnosis of
tuberculous pleurisy, however, are often inefﬁcient. Biochemi-
cal characteristics and cellular components of pleural ﬂuid in
tuberculous pleurisy lack speciﬁcity [1,4]. The levels of adeno-
sine deaminase (ADA), an enzyme associated with T-lympho-
cyte activity, and those of interferon-gamma (IFN-c), a
cytokine secreted by activated T-cells, have been shown to
be increased in, and used to diagnose, tuberculous pleural
effusion [5–14]. However, these increases can also be
observed in other infectious, inﬂammatory or malignant dis-
eases [8,11–19], and are not speciﬁc for tuberculous pleurisy.
The 6-kDa early-secreted antigenic target (ESAT-6) and
culture ﬁltrate protein 10 (CFP10) are antigens preferentially
found in Mycobacterium tuberculosis and virulent Mycobacterium
bovis, but not in M. bovis bacille Calmette–Gue´rin vaccine or
most environmental mycobacteria [20–22]. It has been shown
that ESAT-6 and CFP10 can stimulate peripheral blood mono-
nuclear cells (PBMCs) from patients with tuberculosis to
secrete speciﬁc IFN-c. An ex vivo enzyme-linked immunospot
(ELISPOT) test employing these antigens and detecting IFN-c-
secreting T-cells in peripheral blood [23–27] and bronchoal-
veolar lavage ﬂuid [28] has been found useful in diagnosing
latent and active tuberculosis. The potential of T-cells in pleu-
ral ﬂuid from patients with tuberculous pleurisy to secrete
antigen-speciﬁc IFN-c has been studied only rarely [28].
A prospective study was conducted to evaluate ESAT-6-
and CFP10-speciﬁc IFN-c production by T-lymphocytes in
pleural ﬂuid and peripheral blood from patients with pleural
effusion of undetermined aetiology, using the ELISPOT assay.
The aim was to evaluate the efﬁciency of this assay in the
diagnosis of tuberculous pleurisy.
Materials and Methods
Patients
This prospective study was conducted in a university hospital
of 1500 beds in northern Taiwan, and was approved by the
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Institutional Review Board of the hospital. After written con-
sent had been obtained, patients aged ‡18 years, with pleural
effusion of undetermined aetiology, were enrolled from 1
January to 31 December 2006. Eight millilitres of peripheral
blood was drawn into a tube containing sodium citrate, and
10 mL of pleural ﬂuid that had been aspirated during a diag-
nostic tapping was collected. Standard diagnostic tests for
pleural ﬂuid included chemistry, cell count, differential count,
cytology, and culture of bacteria, including mycobacteria, and
fungi. The ELISPOT assay was performed within 2 h after the
collection of blood or pleural ﬂuid.
PBMC ELISPOT assay
The assay using the ELISPOT kit (T-SPOT-TB; Oxford Im-
munotec Ltd, Oxford, UK) was performed according to
the manufacturer’s instructions. PBMCs were separated
from whole blood using Ficoll–Hypaque, washed, resus-
pended, and counted. PBMCs (c. 250 000/well) were added
to wells coated with a mouse monoclonal anti-IFN-c anti-
body and containing antigen (ESAT-6 or CFP10), mitogen
(phytohaemagglutinin), as positive control, or nothing
(background control wells). After 16–18 h of incubation,
plates were washed. Fifty microlitres of conjugate reagent
containing biotinylated anti-IFN-c monoclonal antibody was
added and incubated for 1 h. The plates were then
washed, and chromogenic alkaline phosphatase substrate
was added. After 7 min, the plates were washed and dried.
Spots were counted manually using a hand-held magnifying
glass. The number of spots in the background control
wells was subtracted from the number in the test wells,
and a response was considered positive if the number of
spots per test well was ‡10 (when the background control
count was <5), or at least twice the value found in the
background control wells (when the background control
count was ‡5).
Pleural ﬂuid ELISPOT assay
Pleural ﬂuid (6–10 mL) was transferred to a 50-mL Falcon
tube. The ﬂuid was diluted with an equal volume of RPMI-
1640 and centrifuged at 430 g for 7 min. The sediment was
suspended with 10 mL of RPMI-1640 and centrifuged at
300 g for 7 min. The sediment was then suspended in
0.7 mL of AIM-V culture medium.
Forty microlitres of the suspension were mixed with an
equal volume of a Trypan blue solution to evaluate the via-
bility of the cells. The T-SPOT-TB assay was performed in
each well (100 lL) containing c. 103–105 cells. The results
were validated by counting the spots from the positive con-
trol well. Subsequent steps were as stated above for
PBMCs.
Diagnosis of tuberculous pleurisy
Tuberculous pleurisy was classiﬁed as conﬁrmed if any of the
following criteria were met: (i) culture of pleural ﬂuid, pleu-
ral biopsy material or sputum yielded M. tuberculosis; (ii) the
histology of pleural biopsy material showed granulomatous
inﬂammation with positive acid-fast bacilli; and (iii) the histol-
ogy of pleural biopsy material showed granulomatous inﬂam-
mation without acid-fast bacilli, but there was obvious clinical
improvement after antituberculous chemotherapy. Tubercu-
lous pleurisy was classiﬁed as probable, if: (i) the culture of
pleural ﬂuid, pleural biopsy material or sputum did not yield
M. tuberculosis; (ii) the pleural biopsy histology showed
chronic inﬂammation without acid-fast bacilli; (iii) there was
obvious clinical improvement after antituberculous chemo-
therapy; and (iv) there was no evidence of other causes of
pleural disease. Clinical improvement was deﬁned as defer-
vescence and disappearance of pleural effusions after antitu-
berculous chemotherapy, without the concomitant use of
other antimicrobials or corticosteroids.
Diagnosis of pleural effusion due to other causes
The diagnosis was based on pleural ﬂuid culture, cytology,
histology of pleural or lung biopsy specimens, or compatible
clinical, radiographic and nuclear medical features.
Statistical analysis
Comparisons of the sensitivities and speciﬁcities of the
PBMC ELISPOT and the pleural ﬂuid ELISPOT assay were
performed using Fisher’s exact test.
Results
Patient characteristics
During the year 2006, there were 40 patients with undeter-
mined pleural effusion who consented to being tested. Nine-
teen (15 males) were diagnosed as having tuberculous
pleurisy (15 conﬁrmed cases, four probable cases); their
average age was 60.5 years (range: 21–102 years). Twenty-
one (12 males) had a non-tuberculous cause of pleural effu-
sion, with an average age of 65.5 years (range: 25–87 years;
p 0.461 compared with tuberculous group). In the tubercu-
lous group, 15 (79%) patients had coexisting diseases, includ-
ing: end-stage renal disease (n = 2); previous stroke (n = 2);
stroke and eosinophilic pneumonitis treated with steroids
(n = 1); benign prostatic hyperplasia (BPH) and chronic
obstructive pulmonary disease (n = 1); BPH and arrhythmia
(n = 1); BPH and hip fracture (n = 1); Parkinson’s disease
and prostatic cancer (n = 1); senile dementia (n = 1); acute
lymphocytic leukaemia; post-bone marrow transplantation
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status (n = 1); diabetes mellitus (n = 1); pneumoconiosis
(n = 1); alcoholism and adrenal insufﬁciency due to use of
steroid-containing alternative medicine (n = 1); and normal-
pressure hydrocephalus with paroxysmal supraventricular
tachycardia (n = 1). All had received <2 weeks of antituber-
culous chemotherapy or were not treated at the time of the
ELISPOT study. Pleural ﬂuids of the patients with tubercu-
lous pleurisy were all exudates, and all except two had ‡76%
lymphocytes in the differential count.
The 21 control patients had the following diagnoses: pul-
monary adenocardinoma (n = 6); small-cell lung cancer
(n = 1); metastatic pleural cancer from the colon (n = 1) and
breast (n = 1); mesothelioma (n = 1); pleural lymphoma
(n = 1); heart failure (n = 3); pulmonary infarction (n = 1);
pleurisy due to Mycobacterium avium–intracellulare complex
(n = 2); cytomegalovirus pneumonia with parapneumonic
effusion (n = 1); and pneumonia with parapneumonic effusion
(unknown aetiology) (n = 3). Multiple specimens (mean, 8;
range, 2–34) from all control patients were culture-negative
for mycobacteria.
Laboratory tests for human immunodeﬁciency virus anti-
bodies were performed in ﬁve patients in the tuberculous
pleurisy group, and in three in the control group. All test
results were negative. Of the remaining 32 patients with
unknown human immunodeﬁciency virus status, 30 had their
white blood cells counted. Only one had a peripheral blood
lymphocyte count <500 (441) · 109/L. The patient, a 62-
year-old man with a history of alcoholism and adrenal insufﬁ-
ciency, had his lymphocyte count performed after antituber-
culous therapy. All of the 40 patients were free of AIDS-
deﬁning illness [29] before December 2007.
Pleural ﬂuid ELISPOT assay
The ELISPOT assay was positive in 18 of the 19 patients with
tuberculous pleurisy (sensitivity: 94.7%), and in three of the
21 controls (speciﬁcity: 85.7%) (Table 1). The only false-nega-
tive result occurred in a 78-year-old man with isolation of
M. tuberculosis from two specimens of pleural ﬂuid, and coex-
isting Parkinson’s disease and prostate cancer. The three
false-positive results occurred in one patient each with
mesothelioma, pulmonary adenocarcinoma, and pleurisy due
to M. avium–intracellulare complex.
PBMC ELISPOT assay
The PBMC ELISPOT assay was performed for all patients
and was successful in all but one with tuberculous pleurisy
(the one with the false-negative pleural ﬂuid ELISPOT result).
The result was positive in 14 of the 18 patients with tuber-
culous pleurisy (sensitivity: 77.8%), and in two of the 21 con-
trols (speciﬁcity: 90.5%). Table 2 lists the four patients for
TABLE 1. Sensitivity and speciﬁcity of the ELISPOT assay in the diagnosis of tuberculous pleurisy
Specimen
tested Cause of pleurisy
No. of cases Sensitivity
(%)
Speciﬁcity
(%)
Positive
predictive
value
Negative
predictive valuePositive Negative
Pleural ﬂuid Conﬁrmed TB (n = 15) 14 1 93.3
Probable TB (n = 4) 4 0 100.0
Total (n = 19) 18 1 94.7a 85.7
Blood Conﬁrmed TB (n = 14b) 11 3 78.6
Probable TB (n = 4) 3 1 75.0
Total (n = 18) 14 4 77.8a 87.5
Pleural ﬂuid Non-TB (n = 21) 3 18 85.7c 94.7
Blood 2 19 90.5c 82.6
TB, tuberculosis.
ap 0.307.
bPeripheral blood mononuclear cells from one patient failed to grow after antigen stimulation in the ELISPOT assay.
cp 0.997.
TABLE 2. Characteristics of four tuberculous patients with false-negative peripheral blood mononuclear cell ELISPOT assay
results
Patient, n Age/sex Coexisting disease
White blood
cell count
Lymphocyte
(%)
Lymphocyte
count Anti-HIV
2 62/M Adrenal insufﬁciency 7600 5.8 441 Not done
Alcoholism
7 87/M Arrhythmia 4150 12.8 531 Not done
Prostate hyperplasia
13 22/M ALL, 63 days post-bone
marrow transplant
3980 14.0 557 –
16 87/M Trigeminal neuralgia 8880 5.7 506 Not done
Prostate hyperplasia
ALL, acute lymphocytic leukaemia; HIV, human immunodeﬁciency virus.
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whom the PBMC ELISPOT assay gave a false-negative result.
All of them had lymphopenia. Twelve of the 14 patients with
a positive PBMC ELISPOT assay result had their white blood
cells counted. Their average lymphocyte count was
1071 ± 250/lL (mean ± standard deviation, range: 622–
1388), in contrast to 509 ± 50/lL (range: 441–557) for the
four lymphopenic patients with a false-negative PBMC ELI-
SPOT result (p <0.001). The false-positive result occurred in
the patient with mesothelioma whose pleural ﬂuid also gave
a positive result, and in one patient with heart failure.
Number of immunospots in the pleural ﬂuid and PBMC ELI-
SPOT assays
In most of the tuberculous patients, the number of immuno-
spots in the pleural ﬂuid ELISPOT assay was much higher
than that in the PBMC ELISPOT assay. The median value of
pleural ﬂuid/PBMC immunospot ratio was 10 for the ESAT-6
antigen (range: 1–250) and 8 for the CFP10 antigen (range:
0.7–42) (data not shown).
Feasibility and sensitivity of the tests for the diagnosis of
tuberculous pleurisy
Table 3 shows the feasibility and yield rate of various tests
used to diagnose tuberculous pleurisy in the patients studied
here.
Pleural biopsy provided a rapid and correct histological
diagnosis in nine of the 12 patients who underwent this pro-
cedure, but was not performed in the other seven tubercu-
lous patients, due to: (i) tendency to bleed in three patients
(two with end-stage renal disease, and one with acute leu-
kaemia); (ii) dementia and inability to cooperate in two
patients; and (iii) refusal by the patient in two cases.
Diagnostic tests that require isolation of M. tuberculosis or
ampliﬁcation of its DNA were all suboptimal in sensitivity.
Fig. 1 shows that the pleural ﬂuid ELISPOT assay was posi-
tive, and thus very helpful in providing a rapid diagnosis, in
nine (90%) of the patients who were either not ﬁt for pleural
biopsy (n = 7) or whose pleural histology was non-diagnostic
(n = 3).
Discussion
Our study showed that an ex vivo assay that allows detection
of ESAT-6/CFP10 antigen-speciﬁc, IFN-c-secreting T-cells in
pleural ﬂuid and blood in 24 h was efﬁcient in diagnosing
tuberculous pleurisy. Previous studies showed that, with
blood samples, the assay had a sensitivity of 87–97% and a
speciﬁcity of 87–100% for diagnosing bacteriologically con-
ﬁrmed pulmonary and extrapulmonary tuberculosis [23–27].
It has also been used with bronchoalveolar lavage ﬂuid sam-
ples and shown to be effective in detecting pulmonary tuber-
culosis [28]. Regarding its usage in pleural effusion,
Wilkinson et al. [30] found that ESAT-6-speciﬁc, IFN-c-
secreting T-cells were concentrated 15-fold in pleural ﬂuid
relative to their blood level in ten patients with known
tuberculous pleurisy, but were absent in eight patients with
known non-tuberculous pleurisy. However, whether this
ex vivo assay can be used clinically to diagnose tuberculosis in
patients with unknown cause of pleural effusion has not been
reported. The present study shows that the ELISPOT assay
performed with pleural ﬂuid samples can diagnose tubercu-
lous pleurisy accurately overnight with a sensitivity of 95%.
When it was performed with blood samples, the sensitivity
was lower, with false-negative results being observed mainly
in patients with lymphopenia.
Unlike the ELISPOT assay, which detects antigen-speciﬁc
IFN-c-secreting T-lymphocytes, biochemical or immunological
tests, e.g. of ADA and IFN-c in pleural ﬂuids, which have been
used to diagnose tuberculous pleurisy, are not speciﬁc for
tuberculosis. A meta-analysis of 40 articles showed that the
sensitivity of ADA testing in pleural ﬂuid for diagnosing tuber-
culous pleurisy varied widely (from 47% to 100%), much like
the speciﬁcity (from 50% to 100%) [9]. False-positive results
occurred mainly in cases of empyema [8,15–17], rheumatoid
pleurisy [15,18], malignancies [8,16], and parapneumonic effu-
sions [16,19]. The sensitivity of IFN-c testing in pleural ﬂuid
for diagnosing tuberculous pleurisy was found to range from
57% to 100%, and the speciﬁcity from 90% to 100%, accord-
ing to a meta-analysis of 13 articles [11]. An IFN-c response
by activated T-cells can be elicited by many different antigens,
and its level can be high in pleural ﬂuids for various reasons,
including parapneumonic and neoplastic effusions, especially
from haematological malignancies [11–14].
TABLE 3. Feasibility and sensitivity of tests used for the
diagnosis of tuberculous pleurisy in the patients of this
study
cDiagnostic test
N (positive)/n
(total)
Sensitivity
c (%)
Sputum acid-fast stain 0/14 0
Pleural ﬂuid acid-fast stain 0/18 0
Pleural biopsy tissue acid-fast stain 3/12 25.0
Bronchial washing acid-fast stain 0/2 0
Sputum culture 7/15 46.7
Pleural ﬂuid culture 8/19 42.1
Pleural biopsy tissue culture 3/8 37.5
Bronchial washing culture 1/2 50.0
Pleural ﬂuid/sputum PCR 0/4
Pleural histologya 9/12 75.0
PBMC ELISPOT assay 14/18 77.8
Pleural ﬂuid ELISPOT assay 18/19 94.7
PBMC, peripheral blood mononuclear cell.
aGranulomatous inﬂammation.
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Thus, a high IFN-c level in pleural ﬂuid is not a ﬁnding spe-
ciﬁc for tuberculous pleurisy.
The ELISPOT assay, in contrast, allows detection of spots
formed by IFN-c secreted by T-cells that have been stimulated
by speciﬁc M. tuberculosis antigens. As a technique that allows
detection of cells of low abundance that secrete various mole-
cules [31], the assay captured IFN-c immediately after it was
secreted, and before it was diluted by the blood or pleural
ﬂuid, or degraded, and it allowed the speciﬁc detection of as
few as ten T-cells per 106 PBMCs, a sensitivity much higher
than that of conventional ELISA [32]. Thus, it could be more
speciﬁc and sensitive than the measurement of non-speciﬁc
ADA or IFN-c in blood or pleural effusion ﬂuid. In the current
study, the pleural ﬂuid ELISPOT assay showed high sensitivity
in diagnosing tuberculosis, whereas the PBMC ELISPOT assay
gave false-negative results in four patients with lymphopenia.
The low lymphocyte count probably contributed to the false-
negative results. On the other hand, the reason for the false-
negative results could be that these four patients were immu-
nosuppressed; one was was alcoholic and had been receiving
exogenous steroids, one had acute lymphocytic leukemia after
marrow transplant, and two were of advanced age (87 years
old). The third possible cause of false-negative results could
have been that tuberculous pleurisy can be a locally contained
disease that has the antigen-speciﬁc T-cells compartmental-
ized in the pleural cavity. Lalvani et al. [23] also reported false-
negative ELISPOT results in lymphopenic patients with pulmo-
nary and/or extrapulmonary tuberculosis.
However, the pleural ﬂuid ELISPOT assay was not affected
by a low lymphocyte count, as this study showed that anti-
gen-speciﬁc, IFN-c-secreting T-cells were concentrated eight-
to ten-fold in pleural ﬂuid as compared with blood. All four
patients with a false-negative blood test were positive
according to the pleural ﬂuid ELISPOT assay.
False-positive PBMC ELISPOT results were obtained for
two patients: one with mesothelioma and the other with
heart failure. The cause of the false-positive response was
not clear. Given the high incidence of tuberculosis in Tai-
wan (74.1/105) [33], the two patients might have been
exposed to M. tuberculosis and may have had latent tubercu-
losis. A false-positive result of the pleural ﬂuid ELISPOT
was obtained for three patients, probably due to the non-
speciﬁc IFN-c present in the effusion before M. tuberculosis
antigen stimulation and trapped at the bottom of the well
immediately after the ﬂuid was added. The immunospots in
the pleural ﬂuids of these three patients were all smaller
than those in true-positive patients, an observation that
might be helpful in the interpretation of results in future
studies.
A deﬁnite diagnosis of tuberculous pleurisy depends on
the demonstration of M. tuberculosis by acid-fast stain of, or
culture from, pleural ﬂuid, sputum or pleural biopsy speci-
mens. The paucity of bacilli in pleural ﬂuid leads to low sensi-
tivity of Ziehl–Neelsen staining (0–5%) [7,34–37], as was also
observed in this study. Pleural ﬂuid culture has a sensitivity
of only 10–37% [4,7,35–37] (42.5% in our study), and
requires 2–8 weeks. PCR can be a rapid diagnostic method.
However, the reported sensitivity of PCR with pleural ﬂuid
varies widely, from 31% to 81% [12,37–40], and in this study
it was zero. Thus, for a rapid diagnosis of tuberculous pleu-
risy, pleural biopsy, followed by histological examination,
which has high sensitivity (54–82%) [4,7,35–37], or PCR
(90% sensitivity) [37], is often needed. It is, nonetheless,
invasive, requires a specialist, and is subject to sampling
error. In this study, histological examination of pleural biopsy
specimens had a 75% diagnostic yield, but could only be per-
formed in 12 (63%) of the 19 patients, and provided a rapid
diagnosis in only nine cases (47%) (Table 3; Fig. 1).
Pleural effusion of undetermined  aetiology: 40
Pleural fluid ELISPOT
positive: 21 
Pleural fluid ELISPOT
negative: 19 
B:TB:1   TB: 18 Non-TB:3 
Biopsy: 
Non-TB: 18 
not done 
Histology 
diagnostic:  9 
Biopsy
not done:
Mesothelioma:  1 Cancer:  8 
Ly mphoma:  1 
Histology 
non-
diagnostic: 3
6
Fluid PCR:
carcinoma:1
MAC*:1
Infarction:  1 
Parapneumonic:  3 
Heart failure:  3 
Sputum
PCR: (–) x 2
Cytomegalovirus:  1 
(–) x 2
Adeno- 
MAC*:1 
FIG. 1. Results of rapid diagnostic tests
(pleural biopsy, pleural ﬂuid PCR, sputum
PCR, pleural ﬂuid ELISPOT assay) in 19
patients with tuberculous (TB) and 21
patients with non-TB pleural effusions.
*MAC, pleurisy due to Mycobacterium
avium–intracellulare complex.
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The ELISPOT assay was especially useful for patients who
could not undergo pleural biopsy, e.g. those with a tendency
to bleeding due to hepatic or renal insufﬁciency, haematolog-
ical diseases or ongoing anticoagulant therapy, those unable
to cooperate due to dementia or mental disorders, those
requiring ventilators, or those whose pleural effusions were
too small in volume for a safe biopsy. ELISPOT assay results
are available overnight, permitting the start of antitubercu-
lous chemotherapy that would probably not be started
empirically, given the underlying hepatic and/or renal diseases
in patients with tendency to bleeding, or multi-organ failure
in patients requiring ventilators.
In summary, the enzyme-linked IFN-c assay using pleural
ﬂuid is an efﬁcient method for diagnosing tuberculous pleu-
risy overnight with a sensitivity and negative predictive value
of nearly 95%, and a speciﬁcity and positive predictive value
of over 85%. This non-invasive assay can be especially helpful
for patients not eligible for pleural biopsy.
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